Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda and Lenvima in recurrent or metastatic head and neck squamous cell carcinoma
NCT05523323Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2020
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lenvatinib in head and neck squamous cell carcinoma (HNSCC), sponsored by Merck & Co.. Started Oct 2020; status: completed.
02
Drugs
lenvatinib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05523323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05523323.